All Children’s Hospital Los Angeles locations are open.
Emotional Support Phone Line for Current Patients, Families and Team Members:
323-361-1121 (no texts)
8 a.m. - 7 p.m.
The Eosinophilic Gastrointestinal Disorder Program at Children’s Hospital Los Angeles provides comprehensive and specialized care for infants, children and teens living with Eosinophilic Esophagitis (EoE) and other Eosinophilic Gastrointestinal Disorders (EGID). Experts from different specialties come together to perform a thorough evaluation and develop a treatment plan tailored to your unique needs.
Eosinophils are a type of blood cell that are a normal part of the immune system. They help us fight certain types of infections such as parasites. When activated by environmental or food triggers, eosinophils can cause allergic inflammation. Their active state is called “degranulating.”
EGID is a group of disorders resulting from an abnormal build-up of eosinophils in the gastrointestinal (GI) tract leading to ongoing inflammation and discomfort. EoE is the most common form of EGID and primarily affects the esophagus.
People with EGID may experience abdominal pain, diarrhea, weight loss, slow growth and mealtime difficulties. People with EoE may experience difficulty swallowing, repeated vomiting, acid reflux symptoms, and food impaction (when food gets stuck in the food pipe or esophagus).
To diagnose EGID we use a combination of laboratory tests, imaging and procedures including endoscopy.
Treatment may include medications, dietary changes, or a combination of both. Each patient is unique, and we work with you to personalize your treatment plan.
We treat these conditions:
Currently, EGID can only be diagnosed by a procedure called endoscopy. Endoscopy uses a camera to visualize the inside of the gastrointestinal (GI) tract and obtain small tissue samples that are examined under a microscope to look for eosinophils. Often, repeated endoscopies are required to evaluate your response to treatment.
At Children’s Hospital Los Angeles, we proudly offer Transnasal Endoscopy (TNE) as an alternative to traditional endoscopy for suitable candidates. We are one of the few EGID programs in the U.S. to offer this procedure. TNE is performed without sedation and offers a way to examine the GI tract without repeated exposures to general anesthesia. For more information, visit the CHLA TNE Program (https://www.chla.org/transnasal-endoscopy-program).
We may recommend other diagnostic tests including:
The type of treatment we recommend varies based on the location of the inflammation, its severity, and your preferences. Treatment options may include medications that reduce inflammation, customized food elimination diets, or a combination of both. See detailed descriptions below.
We work closely with patients and families to determine the best options, whether it is medication and/or dietary changes.
PPIs are medications that reduce the production of stomach acid. They are effective treatment of EoE in likely one of 2 ways: 1. they treat acid reflux that can make EoE worse. 2. PPIs also target the allergic inflammatory pathway involved in EoE. This is commonly referred to as ‘PPI-responsive EoE.’
Steroids are very effective in controlling allergic inflammation. Inhaled steroids are widely used in treating asthma. We use them in a different way to treat EoE. When these preparations are taken by mouth daily, they coat the surface of the esophagus to calm the inflammation resulting from EoE, reducing reactions to EoE triggers. These medications are minimally absorbed and unlikely to cause undesired steroid side effects.
Commonly used topical steroid preparations are:
After taking a swallowed steroid, it is important that you do not eat or drink for at least 30 minutes
Oral systemic steroids may be used to provide more immediate control of inflammation. Prednisone and Prednisolone are absorbed by the body rapidly and are very effective in calming inflammation. However, they also have more side effects and long-term use requires careful monitoring. Budesonide capsule is another oral steroid that is less absorbed and therefore associated with less side effects but can still be effective in treating inflammation in the lower GI tract. Prednisone, Prednisolone, and Budesonide have been used to treat eosinophilic gastritis, enteritis, colitis, or EoE refractory to conventional treatments.
These medications target specific molecules involved in the inflammatory pathway that leads to EGID. Currently, Dupixent (Dupilumab) is the only Food and Drug Administration (FDA)-approved medication for adults and older children with EoE.
Dupixent has been widely used in adults and children with severe eczema and asthma with great success and an excellent safety profile. On May 20, 2022 Dupixent was approved by the Food and Drug Administration (FDA) for treating EoE in selected patients, making it the first FDA-approved medication for EoE. This is an injectable medication you learn to give at home that offers another “steroid-free” option.
There are several other biologic medications that are actively being developed to treat EGID. Some patients may receive these medications as research participants in clinical trials.
We offer state of the art care in a supportive environment to help people and their families living with EGID and EoE. We provide multidisciplinary care with a team of experts from multiple specialties that work together to address the full scope and impact of these conditions. We work with you to develop a comprehensive and personalized treatment plan that best fits with you and your family’s unique needs and challenges.
The multidisciplinary EGID team includes:
Jennifer Hershfield, PhD (Pediatric Psychology)
Jill Madison (Registered Dietician)
Niaz Lavee (EGID RN Coordinator)
As a means of ensuring continuing excellence and state of the art patient care, the Eosinophilic Gastrointestinal Diseases Program at CHLA conducts prospective outcomes research. This is important in making improvements in care to patients seen in our program and other programs. Patients evaluated in our clinic may be consented for participation in this research. Patient information is always protected and confidential and the study is approved by the CHLA Institutional Review Board.
Dietary changes, or nutrition interventions, are an effective treatment for EoE and EGID. There are several stepwise approaches ranging from avoiding one or more food groups, to the most significant and restrictive nutrition intervention, which is an elemental formula-only diet.
When deciding if an elimination diet works for your family, there are several considerations. To help guide your decision, you will meet with a RD (Registered Dietitian) who specializes in organizing food and designing plans to meet the nutritional needs for your child. The RD can provide strategies to identify safe foods, recognize hidden ingredients, and determine appropriate food substitutes to maintain a balanced and nutritionally appropriate diet for ongoing optimal growth.
Additional factors to consider in discussing elimination diets include:
Typically, a food group or groups is eliminated for a minimum of 8-12 weeks before re-scoping to assess the effect of this dietary change. Unfortunately, allergy testing (both skin and/or blood tests) cannot predict which foods should be eliminated. Endoscopic evaluation is the best way to know if a dietary change promotes healing.
Elimination diet categories are detailed below, you’ll note increasing levels of dietary restriction have greater levels of successfully inducing remission or healing.